Recent developments of phosphodiesterase inhibitors: Clinical trials, emerging indications and novel molecules.

ABSTRACT: The phosphodiesterase (PDE) enzymes, key regulator of the cyclic nucleotide signal transduction system, are long-established as attractive therapeutic targets. During investigation of trends within clinical trials, we have identified a particularly high number of clinical trials involving PDE inhibitors, prompting us to further evaluate the current status of this class of therapeutic agents. In total, we have identified 87 agents with PDE-inhibiting capacity, of which 85 interact with PDE enzymes as primary target. We provide an overview of the clinical drug development with focus on the current clinical uses, novel molecules and indications, highlighting relevant clinical studies. We found that the bulk of current clinical uses for this class of therapeutic agents are chronic obstructive

SUBMITTER: Bondarev AD 

PROVIDER: S-EPMC9731127 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature